Translated abstract:
In the ISAR-REACT trial, the use of abciximab in patients undergoing percutaneous coronary intervention (PCI) after pretreatment with 600 mg clopidogrel for more than 2 hours was associated with no clinically measurable benefit at 30 days. As a study observed a survival benefit from abciximab at one year, we analyzed the follow-up at one year of the ISAR-REACT trial. There was no clinical benefit from Abciximab after coronary stent implantation at one year.